Literature DB >> 16075048

A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer.

Ruth Seggewiss1, Cynthia E Dunbar.   

Abstract

Reports of neoplasia related to insertional activation of protooncogenes by retroviral vectors have raised serious safety concerns in the field of gene therapy. Modification of current approaches is urgently required to minimize the deleterious consequences of insertional mutagenesis. In this issue of the JCI, Adjali and colleagues report on their treatment of SCID mice lacking the 70-kDa protein tyrosine kinase, ZAP-70, with direct intrathymic injection of a ZAP-70-expressing T cell-specific lentiviral vector, which resulted in T cell reconstitution. Using lentiviral vectors and in situ gene transfer may represent a safer approach than using retroviral vectors for ex vivo gene transfer into HSCs, avoiding 3 factors potentially linked to leukemogenesis, namely HSC targets, ex vivo transduction and expansion, and standard Moloney leukemia virus-based retroviral vectors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075048      PMCID: PMC1180563          DOI: 10.1172/JCI26041

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods.

Authors:  T Wu; H J Kim; S E Sellers; K E Meade; B A Agricola; M E Metzger; I Kato; R E Donahue; C E Dunbar; J F Tisdale
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

2.  A spontaneously arising mutation in the DLAARN motif of murine ZAP-70 abrogates kinase activity and arrests thymocyte development.

Authors:  D L Wiest; J M Ashe; T K Howcroft; H M Lee; D M Kemper; I Negishi; D S Singer; A Singer; R Abe
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

3.  Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.

Authors:  V Stephan; V Wahn; F Le Deist; U Dirksen; B Broker; I Müller-Fleckenstein; G Horneff; H Schroten; A Fischer; G de Saint Basile
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

4.  Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Authors:  D D Patel; M E Gooding; R E Parrott; K M Curtis; B F Haynes; R H Buckley
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

5.  Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.

Authors:  R H Buckley; R I Schiff; S E Schiff; M L Markert; L W Williams; T O Harville; J L Roberts; J M Puck
Journal:  J Pediatr       Date:  1997-03       Impact factor: 4.406

6.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

7.  Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling.

Authors:  A C Chan; N S van Oers; A Tran; L Turka; C L Law; J C Ryan; E A Clark; A Weiss
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

Review 8.  ZAP-70 and defects of T-cell receptor signaling.

Authors:  M E Elder
Journal:  Semin Hematol       Date:  1998-10       Impact factor: 3.851

9.  The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit.

Authors:  H K Habibian; S O Peters; C C Hsieh; J Wuu; K Vergilis; C I Grimaldi; J Reilly; J E Carlson; A E Frimberger; F M Stewart; P J Quesenberry
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

10.  In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors.

Authors:  Gilles Marodon; David Klatzmann
Journal:  BMC Immunol       Date:  2004-08-19       Impact factor: 3.615

View more
  3 in total

Review 1.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

2.  An alternative method for intrathymic injections in mice.

Authors:  Robin Blair-Handon; Kristen Mueller; Shelley Hoogstraten-Miller
Journal:  Lab Anim (NY)       Date:  2010-08       Impact factor: 12.625

Review 3.  [Role of gene therapy in trauma and orthopedic surgery].

Authors:  A Oberholzer; P Stahel; S K Tschöke; W Ertel
Journal:  Unfallchirurg       Date:  2006-07       Impact factor: 1.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.